Director, RLT LCM Strategy
The Director, RLT LCM Strategy is responsible for providing Competitive Intelligence (CI) and Readiness leadership rooted in deep understanding of the external competitive environment and our internal product/ portfolio strategies, with a focus on the disease Area. This individual also leads future life cycle planning for new indications/trials, and will develop deep forward-looking competitive intelligence readiness.
The primary objective is to provide a future looking state of readiness to: 1) anticipate and act on external macro-environmental market changes, competitor new launches and other competitor strategies in a legal and compliant manner, 2) Ensuring all ongoing and new trials are using a US-first mindset, and 3) exploring and evaluating all new BD&L opportunities to ensure Novartis leadership in the RLT space. The individual performs these functions independently and at a high level of achievement.
This role requires a highly motivated individual who can work with a high degree of autonomy, in a dynamic environment utilizing creative problem-solving skills and industry knowledge. Additionally, the ideal candi-date will possess a portfolio mindset, deep scientific acumen, knowledge of clinical development principles, and the ability to identify BD opportunities along with the BD&L team beyond existing tumors. This leader is a proactive custodian for consistent competitive readiness excellence and looks to continuously improve on our business readiness across functions.
Your responsibilities include, but are not limited to:
• Anticipate and develop defensive strategies against any long-term competitive threats to the RLT business across brands. Develop effective business and competitive intelligence for the product/ portfolio across relevant functions to provide unbiased and fact-based competitive insights.
• Represent US- voice on GPT for existing and new trials; evaluating impact on US business of all new development opportunities
• Provide guidance and lead with BD&L team to identify external opportunities to expand RLT portfolio beyond the existing brands, both for clinical collaboration opportunities as well as for licensing/acquisition opportunities
• Proactive surveillance of relevant Disease Area portfolio healthcare environment issues including pol-icy, regulatory, health technology to identify key issues relevant to strategic planning initiatives in the US. Partner with internal stakeholders and external thought leaders to explore opportunities to grow competitive share, increase impact and improve profitability for Disease Area portfolio
This is a US based position. No international relocation will be provided for this position.
This position will be located at the East Hanover site and will not have the ability to be located remotely. This position will require 10-20% travel as defined by the business (domestic and/ or international).